BioSpace News Archive

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company’s 13,333,334 shares of common stock of Evofem Biosciences, Inc. (“Evofem”) (Nasdaq: EVFM), which represented approximately 26.7% of the outstanding shares of Evofem common stock a

AVITA Medical Limited ( Company ) (ASX:AVH) (NASDAQ:RCEL) today announced that management will present virtually at the upcoming Jefferies Virtual Health Conference on Wednesday, June 3, 2020 at 4:30 p.m. EDT. Authorised for release by the Chief Financial Officer of AVITA Medical Limited. ABOUT AVITA MEDICAL LIMITED AVITA Medical is a regenerative medicine company with a techno

ContraFect Corporation, a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase additional shares of its common stock.

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”) today announced the appointment of Pavel Raifeld as Chief Executive Officer effective May 20, 2020. Mr. Raifeld is a seasoned healthcare executive with a strong background in strategy, business development and corporate finance and has focused much of

Dutch Bros Coffee and its customers joined together to raise $1.39 million for the Muscular Dystrophy Association on the company’s 14th annual Drink One For Dane day held on May 8. More than 390 shops in seven states joined together with customers to support ALS research, patient care and advocacy.

Option Care Health, Inc., the nation’s largest independent provider of home and alternate site infusion services, has been selected by UroGen Pharma as a preferred national pharmacy provider to prepare and deliver a first-of-its-kind cancer treatment, Jelmyto™ for pyelocalyceal solution.

PPD, Inc., a leading global contract research organization, announced that Jaguar Holding Company II and PPD Development, L.P., both indirect wholly owned subsidiaries of the Company, successfully upsized and finalized the terms of the Co-Issuers’ offering of $500 million aggregate principal amount of 4.625% senior notes due 2025 and $700 million aggregate principal amount 5.000% senior notes due 2028.

Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) has approved KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD).

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has determined that the latest proposal from Melinta Therapeutics, Inc

BC Platforms and Kaiser Permanente today announced they are winners of the 2020 Microsoft Health Innovation Award in the Reimagine Health Category for enabling a unique way of pairing clinical and genomic data on the same platform to advance precision medicine capabilities.